|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
National Heart, Lung, and Blood Institute (NHLBI) |
|---|---|
| Information provided by: | National Institutes of Health Clinical Center (CC) |
| ClinicalTrials.gov Identifier: | NCT00001618 |
Purpose
Bronchoalveolar lavage (BAL) is a diagnostic and therapeutic procedure conducted by placing a small fiberoptic scope into the lung of a patient, and injecting sterile water (saline) into the lung and removing the fluid. The sterile solution removed contains secretions, cells, and protein from the lower respiratory tract. This sample can be analyzed to provide more information about possible disease processes going on in the lungs.
This protocol will be used to perform BAL, bronchial brushing, and bronchial wall biopsy in normal volunteers and patients with pulmonary disease. The samples collected during the study will be used to examine biochemical processes in the lung that may contribute to lung disease
| Condition |
|---|
|
Asthma Pulmonary Fibrosis |
| Study Type: | Observational |
| Official Title: | Segmental Bronchoalveolar Lavage |
| Study Start Date: | November 1996 |
This protocol proposes to perform bronchoalveolar lavage, bronchial brushing and bronchial wall biopsy in research volunteers and in patients with pulmonary disease to evaluate the cellular components of normal and diseased lungs. This research study will help to improve our understanding of pathogenic mechanisms in the lung during progression of pulmonary disease.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Patients and research volunteers will be accepted for bronchoscopy and bronchoalveolar lavage only if their heath status will not be compromised by the procedure.
EXCLUSION CRITERIA:
Patients or research volunteers with abnormalities that contraindicate, or increase the risk of, fiberoptic bronchoscopy and bronchoalveolar lavage, including a history of allergy to atropine, lidocaine, or other topical anesthetics or premedications; FEV(1) less than 0.8 liters; PaO(2), on supplemental 02, of less than 70 mmHg or PaCO(2) greater than 45 mmHg; presence of uncorrected clotting disorder, uncontrolled hypertension, significant cardiac disease, renal or liver failure; metastatic disease; hematologic disorders such as severe anemia (hemoglobin less than or equal to 7 g/ml), granulocytopenia, or platelet disorders.
Patients or research volunteers with a positive serum test for human immunodeficiency virus or hepatitis B or C.
Patients or research volunteers who are pregnant or lactating.
Patients or research volunteers incapable of giving informed consent .
Contacts and Locations| Contact: Patient Recruitment and Public Liaison Office | (800) 411-1222 | prpl@mail.cc.nih.gov |
| Contact: TTY | 1-866-411-1010 |
| United States, Maryland | |
| National Institutes of Health Clinical Center, 9000 Rockville Pike | Recruiting |
| Bethesda, Maryland, United States, 20892 | |
More Information
| Study ID Numbers: | 970022, 97-H-0022 |
| Study First Received: | November 3, 1999 |
| Last Updated: | September 6, 2008 |
| ClinicalTrials.gov Identifier: | NCT00001618 |
| Health Authority: | United States: Federal Government |
|
Cystic Fibrosis Healthy Volunteers Asthma Normal Volunteer Chronic Lung Disease |
|
Lung Diseases, Interstitial Fibrosis Asthma Healthy Pulmonary Fibrosis Lung Diseases, Obstructive Hypersensitivity |
Cystic Fibrosis Respiratory Tract Diseases Lung Diseases Hypersensitivity, Immediate Cystic fibrosis Respiratory Hypersensitivity |
|
Pathologic Processes Immune System Diseases Bronchial Diseases |
